AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31607720
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (NSS) applied to the wound after tooth extraction
Trial: 18694136
Drug: Non-interruptive alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-interruptive alert within electronic medical record prompting lab orders with new prescriptions
Trial: 16821203
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (transsphenoidal surgery)
Trial: 16821203
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (Sandostatin LAR, 20 mg im, monthly)
Trial: 10350382
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of meropenem: 2 g iv loading dose followed by 3 g continuous infusion over 24 h
Trial: 10350382
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration (IA) of meropenem: 2 g iv every 8 h
Trial: 8596317
Drug: Subcutaneous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days)
Trial: 8596317
Drug: Subcutaneous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin (Fragmin)
Trial: 1959860
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glucagon therapy (30 U insulin and 3 mg glucagon in 250 ml 5% dextrose over 12 hr each day for 3 wk)
Trial: 1959860
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical regime to insulin and glucagon)
Trial: 786190
Drug: Steroid-treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-treated group (DMP + MPS)
Trial: 31755948
Drug: Rifampin therapy
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin therapy for at least 14 days within 90 days of diagnosis
Trial: 31755948
Drug: No rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rifampin therapy
Trial: 26477692
Drug: ETABJ (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETABJ (matched etanercept and 50 ml blueberry juice daily)
Trial: 26477692
Drug: ETA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETA (50 mg of etanercept twice weekly)
Trial: 17189962
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus venlafaxine
Trial: 15371578
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a monotherapy (180 microg once weekly)
Trial: 15371578
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a plus lamivudine (100 mg daily)
Trial: 15371578
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (100 mg daily)
Trial: 11773925
Drug: Angina clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angina clinic (optimized antianginal medications)
Trial: 9842823
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 5 microg/kg 90 min before spinal anesthesia
Trial: 8080740
Drug: Intact A5B7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact A5B7 IgG1 mouse monoclonal antibody (MAb) to CEA
Trial: 8080740
Drug: F(ab')2 fragment
RxNorm normalized name: Anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F(ab')2 fragment of the same antibody
Trial: 2757960
Drug: Stage C
RxNorm normalized name: TITANIUM DIOXIDE 0.234 g in 100 g TOPICAL STICK [ALL ABOUT SOO SUN STAGE COOLSTICK SPF50 PA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage C treatment
Trial: 2757960
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and response to treatment
Trial: 862429
Drug: Synemol cream
RxNorm normalized name: fluocinolone acetonide Topical Cream [Synemol]
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synemol cream (0.025%)
Trial: 862429
Drug: Diproson cream
RxNorm normalized name: Alclometasone Dipropionate
DrugBank: Alclometasone (DB00240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diproson cream (0.05%)
Trial: 862429
Drug: Aristocort‐A cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aristocort‐A cream (0.5%)
Trial: 862429
Drug: Valisone cream
RxNorm normalized name: Valine
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valisone cream (0.1%)
Trial: 31675420
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptive Pills (COCPs)
Trial: 30992659
Drug: KM-819 (FAS-associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-819 (FAS-associated factor 1 inhibitor)
Trial: 27755057
Drug: Programmed Intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed Intermittent Epidural Bolus (PIEB) of 10 mL of bupivacaine 0.0625% with fentanyl 2 μg/mL
Trial: 23800977
Drug: perindopril 10
RxNorm normalized name: amlodipine-perindopril 10 mg-14 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril 10 mg/day
Trial: 21711255
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment from day 1 without detoxification
Trial: 21711255
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient detoxification program without preventive treatment from day 1
Trial: 31307393
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment
Trial: 18353314
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg reteplase in 300 mL Ringer's lactate
Trial: 18353314
Drug: 300 mL
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mL Ringer's lactate only
Trial: 16442897
Drug: Glucose-insulin-potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK) infusion during primary PCI
Trial: 12562449
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily for 4 weeks
Trial: 8490078
Drug: Placebo, H2-antagonists,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, H2-antagonists, or omeprazole
Trial: 29344879
Drug: Placebo 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg/day
Trial: 27956407
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment for 12 weeks
Trial: 17043834
Drug: 10% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% urea lacquer applied once daily for 28 days
Trial: 17043834
Drug: 10% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% urea lacquer applied twice daily for 28 days
Trial: 12393429
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with fludarabine and rituximab
Trial: 12393429
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with fludarabine followed by rituximab
Trial: 10513457
Drug: Fananserin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fananserin (600 mg/day) with slow titration (100 mg increases every 3 days)
Trial: 10513457
Drug: Fananserin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fananserin (600 mg/day) with rapid titration (200 mg increases every 3 days)
Trial: 10513457
Drug: Fananserin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fananserin (600 mg/day) with intermediate titration (100 mg increases every 2 days)
Trial: 10513457
Drug: Fananserin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fananserin (multiple doses)
Trial: 2898027
Drug: Cholestyramine resin
RxNorm normalized name: Cholestyramine Resin
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine resin (12 g, twice a day)
Trial: 2898027
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg, twice a day)
Trial: 2898027
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg, twice a day)
Trial: 30060902
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (CLA): clarithromycin 500mg, lansoprazole 30mg, amoxicillin 1g, all bid for 10 days
Trial: 30060902
Drug: Levofloxacin-based therapy
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based therapy (PLA): pantoprazole 80mg, levofloxacin 500mg, azithromycin 500mg, all od for 10 days
Trial: 28588166
Drug: Local steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid injection (triamcinolone acetate)
Trial: 25577713
Drug: Bupivacaine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.3 mL per side, intranasally)
Trial: 25577713
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (0.3 mL per side, intranasally)
Trial: 17116021
Drug: RWJ-333369 (100-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-333369 (100-750 mg)
Trial: 17116021
Drug: RWJ-333369 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-333369 (750 mg)
Trial: 17116021
Drug: RWJ-333369 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-333369 (750 mg) under fed conditions
Trial: 9209786
Drug: Clarithromycin (CAM)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CAM) 400 mg/day, orally
Trial: 9209786
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (non-CAM)
Trial: 7957544
Drug: Umespirone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umespirone 20 mg
Trial: 7957544
Drug: Umespirone 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umespirone 80 mg
Trial: 3624110
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg single oral dose)
Trial: 3624110
Drug: Ampicillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (2 g single oral dose and 500 mg four times per day for five days)
Trial: 21782948
Drug: Sub-antimicrobial-dose doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-antimicrobial-dose doxycycline (SDD) for 3 months
Trial: 21782948
Drug: Antimicrobial-dose doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimicrobial-dose doxycycline (ADD) for 2 weeks
Trial: 15131558
Drug: Oral rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rosiglitazone for 6 months
Trial: 15131558
Drug: Oral rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rosiglitazone
Trial: 11296803
Drug: Standardized exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized exercises (SE) and slider board (SB) therapy
Trial: 9310811
Drug: Apnoea tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apnoea tests without CO2 augmentation (group A)
Trial: 9310811
Drug: Apnoea tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apnoea tests with CO2 augmentation (group B)
Trial: 8317029
Drug: Buprenorphine (priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (priming dose i.m. at wound closure, sublingual buprenorphine every eight hours)
Trial: 8317029
Drug: Morphine (priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (priming dose i.m. at wound closure, sublingual placebo every eight hours)
Trial: 2873106
Drug: Extempore combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extempore combination of salbutamol syrup plus 30‐mg oxatomide tablets
Trial: 2873106
Drug: 30‐mg oxatomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐mg oxatomide tablets alone
Trial: 31511891
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in rHEMI+ patients
Trial: 31511891
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in rHEMI- patients
Trial: 31511891
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment for rHEMI+ vs rHEMI- patients
Trial: 23701262
Drug: GSK256073 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 5 mg BID
Trial: 23701262
Drug: GSK256073 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 10 mg QD
Trial: 23701262
Drug: GSK256073 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 25 mg BID
Trial: 23701262
Drug: GSK256073 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 50 mg QD
Trial: 11174230
Drug: Sublingual hyoscyamine
RxNorm normalized name: hyoscyamine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual hyoscyamine sulfate (0.125 mg) with ketorolac tromethamine (30 mg IV)
Trial: 11174230
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with ketorolac tromethamine (30 mg IV)
Trial: 9670686
Drug: Laferon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laferon therapy as part of complex treatment schemes
Trial: 31437865
Drug: Tegoprazan 400
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 400 mg
Trial: 31437865
Drug: Tegoprazan 100
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 100 mg (multiple doses)
Trial: 31437865
Drug: Tegoprazan 200
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 200 mg (multiple doses)
Trial: 31437865
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg (control)
Trial: 26498603
Drug: 6-h magnesium
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-h magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 6 h)
Trial: 26498603
Drug: 24-h conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h conventional magnesium sulfate therapy (4 g loading dose followed by 1 gm/h infusion for 24 h)
Trial: 15448985
Drug: Alendronate (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5-20 mg/day, with over 95% receiving 5 or 10 mg/day)
Trial: 1761174
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of metronidazole (500 mg vaginal suppository) before hysterectomy
Trial: 7043104
Drug: Weight-reduction treatment
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-reduction treatment program with diet instruction and weekly meetings with a dietitian for 16 months
Trial: 27979041
Drug: Wait-and-see approach
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-and-see approach (rate control medication until spontaneous conversion, with possible cardioversion within 48 hours)
Trial: 25945079
Drug: Acute magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute magnesium supplementation (300 mg/d for 1 week)
Trial: 25945079
Drug: Chronic magnesium
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic magnesium supplementation (300 mg/d for 4 weeks)
Trial: 19122548
Drug: Butorphanol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (n = 96): intravenous loading dose of 10 microg kg(‐1) butorphanol followed by infusion of 2 microg kg(‐1) h(‐1) butorphanol combined with intravenous PCA set at a bolus of 0.02 mg kg(‐1) morphine
Trial: 15352914
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg continuous
Trial: 11434941
Drug: Intralipid 10%
RxNorm normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid 10% (1.5 ml/min)
Trial: 9887454
Drug: 5-year therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-year therapy
Trial: 8556965
Drug: Amantadine 200
RxNorm normalized name: amantadine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 200 mg p.o. daily
Trial: 8556965
Drug: Amantadine 200
RxNorm normalized name: amantadine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 200 mg p.o. bid
Trial: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
RxNorm normalized name: Auro Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurokeratinate (Auro-Detoxin) administered intramuscularly at slowly rising doses
Trial: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
RxNorm normalized name: Auro Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurokeratinate (Auro-Detoxin) at 25 mg gold twice weekly
Trial: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
RxNorm normalized name: Auro Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurokeratinate (Auro-Detoxin) at 65 mg gold once a month
Trial: 7351166
Drug: Aurokeratinate (Auro-Detoxin)
RxNorm normalized name: Auro Ear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aurokeratinate (Auro-Detoxin) at 50 mg gold every 14 days as maintenance dose
Trial: 20573925
Drug: Pharmacotherapy-EBL group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy-EBL group (continuation of vasoactive-drug therapy, propranolol or nadolol, long-term endoscopic band ligation)
Trial: 20573925
Drug: Pharmacotherapy-EBL group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy-EBL group
Trial: 16807023
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus, one inhalation twice daily for 12 weeks
Trial: 16807023
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg and Fluticasone propionate 500 microg Diskus plus 20 mg Enoxaparin administered subcutaneously once daily for 12 weeks
Trial: 10997957
Drug: ANDRO‐6 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANDRO‐6 (300 mg androstenedione, 150 mg DHEA, 750 mg Tribulus terrestris, 625 mg Chrysin, 300 mg Indole‐3‐carbinol, 540 mg Saw palmetto)
Trial: 1735264
Drug: Verapamil, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 120 mg three times daily
Trial: 6694008
Drug: Low-pressure spray
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-pressure spray irrigation of corn fields with partially treated wastewater
Trial: 6694008
Drug: Workers cleaning
RxNorm normalized name: Apis cerana worker secretion preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Workers cleaning spray nozzles
Trial: 26933301
Drug: DSS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSS and ESS administered together
Trial: 17216221
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) 2 g/day for 3 months
Trial: 9339678
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Trial: 9339678
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (treatment only after another seizure)
Trial: 9339678
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment and delayed treatment